Byron Zhao Phones & Addresses
-
Elk Grove, CA
-
Union City, CA
-
Houston, TX
-
Sugar Land, TX
-
San Jose, CA
-
Fremont, CA
-
Solon, OH
-
Hollywood, CA
-
Antioch, CA
-
Hayward, CA
-
Pittsburg, CA
Business Records
Name / Title
Company / Classification
Phones & Addresses
President, Director
INSPIRIT FOUNDATION
Civic and Social Associations · Civic/Social Association
Civic and Social Associations · Civic/Social Association
15530 Truslow Pt Ln, Sugar Land, TX 77478
President, Director
Lord's Favor Christian Church
Religious Organization
Religious Organization
4412 Canonsburg, League City, TX 77573
Publications
Us Patents
Preferential Inhibition Of Presenilin-1
View pageUS Patent:
20080045499, Feb 21, 2008
Filed:
Feb 6, 2007
Appl. No.:
11/671926
Inventors:
Byron Zhao - Sugar Land TX, US
Mei Yu - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Mei Yu - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
International Classification:
A61K 31/18
A61K 31/55
A61P 25/28
C07C 311/16
C07D 223/10
C07D 401/12
C07K 14/00
C07K 16/00
C12Q 1/02
A61K 31/55
A61P 25/28
C07C 311/16
C07D 223/10
C07D 401/12
C07K 14/00
C07K 16/00
C12Q 1/02
US Classification:
514212030, 435029000, 514212040, 514604000, 514789000, 530324000, 530387900, 530389100, 540522000, 540524000, 540527000, 564092000
Abstract:
The invention provides methods for determining whether an agent preferentially inhibits Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase. The invention also provides agents that preferentially inhibit Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. The invention also discloses that the N-terminal domain of presenilin-1 and -2 determines the difference in the production of Aβ by PS1-comprised and PS2-comprised gamma secretases. This finding identified the structural determinant for the observed difference in the production of Aβ by PS1-comprised and PS2-comprised gamma secretases. Such structural determinant was not identified before. This invention also provides a method for determining whether an agent specifically binds the N terminus of PS1. The invention further provides for methods of treatment of Alzheimer's Disease by administration of an effective dose of an agent which specifically binds PS1, thereby inhibiting PS1 activity.
Potassium Channel Subunit Polypeptide And Polynucleotide Compositions And Uses Therefor
View pageUS Patent:
6610827, Aug 26, 2003
Filed:
Oct 28, 1998
Appl. No.:
09/181339
Inventors:
John R. Forsayeth - San Francisco CA
Byron Zhao - Menlo Park CA
Raymond A. Chavez - Alameda CA
Byron Zhao - Menlo Park CA
Raymond A. Chavez - Alameda CA
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07K 100
US Classification:
530350
Abstract:
The present invention provides novel potassium channel subunits (denoted Kv-SL1 and Kv-SL2, and collectively as Kv-SL) and polynucleotides which identify and encode them. The invention also provides expression vectors and host cells comprising nucleic acid sequence encoding Kv-SL. The invention also provides antibodies of Kv-SL and methods of diagnosing and treating diseases associated with expression of Kv-SL, and screening assays employing the protein, nucleotide, and antibody compositions.